Skip to main content
. Author manuscript; available in PMC: 2009 Oct 12.
Published in final edited form as: Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3271–3278. doi: 10.1158/1535-7163.MCT-07-0352

Figure 3. Functional assays of the effects of selected compounds on ABCG2, Pgp, and MRP1.

Figure 3

Column 1: ABCG2 transfected cells were incubated in BODIPY-prazosin in the absence (shaded histogram) or presence of 0.1 (heavy solid line), 1 (solid line), or 10 μM (dashed line) of NSC11668, NSC19139, NSC120688, NSC168201 or NSC375985 as detailed in the methods section. FTC (10 μM, bottom histogram) is shown as a positive control for ABCG2 inhibition. Column 2: ABCG2 transfected cells were incubated with unlabeled 5D3 antibody (1:3500) in the absence (solid line) or presence (dashed line) of 20 μM of the desired compound after which cells were incubated in APC-labeled secondary antibody. FTC (bottom histogram) at a concentration of 20 μM is shown as a positive control. Column 3: MDR1-transfected cells were incubated in 0.5 μg/ml rhodamine 123 in the absence (solid line) or presence (dashed line) of 10 μM of the desired inhibitor as detailed in the methods. Valspodar at 3 μg/ml is included as a positive control for Pgp inhibition (bottom histogram). Column 4: MRP1-transfected cells were incubated in 200 nM calcein AM in the absence (solid line) or presence (dashed line) of 10 μm of the compounds. MK-571 (25 μM) is shown (bottom histogram) as a positive control for inhibition of MRP1 transport.